Editorial: Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond by Grandi, E. et al.
EDITORIAL
published: 08 June 2018
doi: 10.3389/fphys.2018.00678
Frontiers in Physiology | www.frontiersin.org 1 June 2018 | Volume 9 | Article 678
Edited by:
Geoffrey A. Head,




University of Leeds, United Kingdom
Osmar Antonio Centurion,






This Research Topic is dedicated to
the memory of Dr. J. Jeremy Rice, our
wonderful friend and colleague.
Specialty section:
This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology
Received: 19 April 2018
Accepted: 15 May 2018
Published: 08 June 2018
Citation:
Grandi E, Morotti S, Pueyo E and
Rodriguez B (2018) Editorial: Safety
Pharmacology – Risk Assessment QT
Interval Prolongation and Beyond.
Front. Physiol. 9:678.
doi: 10.3389/fphys.2018.00678
Editorial: Safety Pharmacology – Risk
Assessment QT Interval Prolongation
and Beyond
Eleonora Grandi 1*, Stefano Morotti 1, Esther Pueyo 2 and Blanca Rodriguez 3
1Department of Pharmacology, University of California, Davis, Davis, CA, United States, 2 Biomedical Signal Interpretation
and Computational Simulation Group, Aragón Institute of Engineering Research, IIS Aragón, University of Zaragoza,
Zaragoza, Spain, 3Department of Computer Science, University of Oxford, Oxford, United Kingdom
Keywords: cardiotoxicity, QT interval prolongation, drug-induced arrhythmia, multi-scale modeling, cardiac
electrophysiology
Editorial on the Research Topic
Safety Pharmacology – Risk Assessment QT Interval Prolongation and Beyond
THE NEED OF NEW PARADIGMS FOR CARDIAC SAFETY
The scope of safety pharmacology is to predict whether a drug is likely to cause potentially
lethal adverse effects if administered to humans. While safety pharmacology has broadened its
interests in recent years to the whole cardiovascular, respiratory, and central nervous systems
(and is now extending to other body functions), a major focus since its inception has been
assessing drug-induced prolongation in the QT interval—a surrogate biomarker for torsades
de pointes (TdP) liability. Because the vast majority of drugs that can cause QT prolongation
inhibit hERG channels, current regulatory guidelines concerning cardiac safety recommend
that all compounds are evaluated in vitro for their hERG inhibitory potency (Redfern et al.,
2003) and in vivo for their ability to cause QT/QTc interval prolongation (Food and Drug
Administration, 2005) in an appropriate animal model and in humans. However, it has now
become apparent that QT/QTc prolongation and hERG block are an insufficient proxy for
TdP risk. While the current approach based on these markers has been successful in terms
of preventing TdP risk, this regulatory paradigm might lead to withdrawal from the drug
development pipeline and clinical use of potentially safe drugs. There is therefore a crucial need
to develop a more accurate assessment of proarrhythmic potential of drugs. Notably, in 2014 the
Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative was proposed as a new strategy
by expert working groups sponsored by the US Food and Drug Administration (FDA), the
Cardiac Safety Research Consortium (CSRC), and the Health and Environmental Science Institute
(HESI), and has quickly become a global effort, also involving many industry and academia
partners (Sager et al., 2014). CiPA aims at developing and validating a new paradigm for cardiac
safety evaluation of new drugs that provides a more accurate and comprehensive mechanistic-
based assessment of proarrhythmic (rather than QT prolonging) potential of drugs (Gintant
et al., 2016). This involves assessment of (i) high-throughput in vitro screening of drug effects
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on multiple human ion channels, (ii) coupled with in silico
modeling of human cardiac myocytes to assess integrated
electrophysiological responses, and (iii) verification of predicted
responses in human induced pluripotent stem cell derived
cardiomyocytes (hiPSC-CMs). Safety pharmacology has evolved
in recent years to identify and incorporate new technologies for
clinical and non-clinical applications, including refinement of
ex vivo and in vitro assays and screens, in vivo models, non-
invasive clinical modalities, and in silico approaches. Here we
collected a series of review, perspective, and original research
articles that summarize the state of our knowledge and the latest
advances in these technologies, and how these might contribute
to shaping new and improved cardiac safety guidelines.
MULTISCALE MODELING FOR SAFETY
PHARMACOLOGY
There is a wide range of length and time scales covered in this
Research Topic, from the atom and ns to the whole organism
and month/year (Figure 1 top left to bottom right), all of
which are relevant to safety pharmacology. Structural studies,
including modeling of ion channel gating (Perissinotti et al.) and
interactions with drugs, and drug partitioning, are critical for
drug discovery efforts, and perhaps also a necessary approach
for safety considerations. For example, the study by DeMarco
et al. utilized all-atom molecular dynamics simulations to show
that ionization of drug molecules (specifically Sotalol) can
significantly affect their membrane permeability and partitioning
kinetics, and should therefore be a consideration in ongoing in
silico safety pharmacology efforts. Given the complexity of the
interaction between drugs and ion channels, the drug binding
kinetics, state dependent binding, and temperature dependence
could significantly alter drugs’ impact on the action potential
(AP), even when drugs display similar steady-state block. Lee
et al. highlighted some of the challenges involved in modeling
of the hERG channel and also discussed limitations and need for
improved voltage-clamp protocols to characterize drug-channel
interaction in in vitro experiments. Ellinwood et al. looked at the
consequences of drug binding kinetics and state dependence of
KV1.5 targeting drugs on atrial electrophysiology, and revealed
that ionic remodeling also affects the degree of efficacy and safety
of state-specific IKur inhibitors, by modifying the AP trajectory.
These studies highlight the potential need for extraordinary detail
in the in vitro characterization for accurate in silico prediction
of (cardiac-region specific, Morotti et al., 2016; Ellinwood et al.,
2017; Ellinwood et al.) drug effects on channels and cardiac
electrophysiology.
While the ion channel gating and drug-interaction models
might require further refinement and increased complexity,
significant efforts have been put forward to improve existing
cardiomyocyte models and to take advantage of the existence
(and convergence) of competing mathematical models to narrow
hypotheses or explore alternative hypotheses (Sarkar and Sobie,
2011; Sánchez et al., 2012; Gemmell et al., 2014; Mann et al.,
2016; Pueyo et al., 2016a,b; Gong et al., 2017; Muszkiewicz et al.,
2017). For example, recent work has shown that, when forced
to reproduce the same data, three competing models of human
ventricular myocytes (Ten Tusscher and Panfilov, 2006; Grandi
et al., 2010; O’Hara et al., 2011) became substantially more
similar than they were originally (Mann et al., 2016). Notably,
the work by Krogh-Madsen et al. used clinical congenital LQT
data (as done by Mann et al., 2016) and physiological constraints
on intracellular ionic concentrations to optimize parameters in
the O’Hara-Rudy (ORd) human model (O’Hara et al., 2011).
This in turn improved the accuracy and robustness of TdP
risk prediction (Lancaster and Sobie, 2016), which the authors
attributed to the importance of Ca2+ dynamics in repolarization
and to an improved balance of IKs vs. IKr in the new model.
A different parameterization of the ORd model by Dutta et al.
and Dutta et al. also yielded a better correspondence with
drug response data and improved the identification of pro-
arrhythmic drugs. The authors developed a new metric qNet,
which quantifies the net electronic charge carried by major
inward and outward ionic currents during the steady state AP,
to separate low-, intermediate-, and high-risk hERG blockers.
A follow up study appraised the robustness of qNet as a
biomarker for TdP by considering how uncertainty in the model
parameters propagates to the phenotype level (Chang et al.).
The authors were thus able to identify the conditions under
which decisions on risk can be made reliably and objectively.
Yet, questions remain regarding the physiological meaning of
this new metric, and whether multiple metrics should be utilized
that account for a broader range of behaviors and mechanisms.
Tixier et al. used an in silico model of multi-electrode array
electrophysiology and machine learning to identify predictive
biomarkers that should be measured to improve classifications
of drugs. These investigations add to several previous efforts
to build computational frameworks for assessment of TdP risk
(Mirams et al., 2011; Kramer et al., 2013; Lancaster and Sobie,
2016). On the other hand, Parikh et al. showed that a simpler
classification method based on direct features (ion channel block
information) performed with comparable or higher accuracy
than existing methods based on simulated metrics. One potential
limitation of this approach is that direct feature classifiers might
fail identifying the proarrhythmic risk of drugs affecting channels
that are not included in the training set, whereas predictive
modeling is more likely to yield an accurate classification.
Biophysical modeling can not only provide means for
drug classification, but also understanding of the mechanistic
underpinning of drug responses, as in the multiscale simulations
by Ni et al. and Colman et al. These studies are important
reminders that AP duration changes are rarely homogenous
(e.g., there exist gradients—transmurally, or from base to apex)
and can increase the tissue-level substrates for arrhythmias
(Antzelevitch, 2005; Glukhov et al., 2010). Indeed, multiscale
in silico models can be very powerful tools to investigate the
response of candidate antiarrhythmic compounds at the level of
the electrocardiogram (ECG). The simulated data may also serve
to identify novel ECG-derived biomarkers detecting block of
inward and/or outward currents based on ECG features (Vicente
et al., 2016). Using Langendorff perfused ex vivo rabbit hearts
the Fenton group measured and analyzed the complex dynamics
of spatially discordant alternans, which provide the substrate
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FIGURE 1 | Approaches to predicting drug cardiotoxicity. The Research Topic includes: (1) studies of ion channel structure and function and drug interaction, ranging
from atomistic models to kinetic models of whole-cell ion currents (Top); (2) mechanistic models of single cardiac myocyte electrophysiology, development of metrics
for quantification of torsadogenic risk, and population-based approaches accounting for cell-to-cell variability (Middle); and (3) tissue/organ/organism level studies
spanning tissue-level to whole heart and torso simulations, ex vivo recordings in animal preparations, and human clinical trials (Bottom).
for reentrant arrhythmia (Uzelac et al.) The authors noted that
current AP models fail to reproduce some key dynamics such
as voltage amplitude alternans, smooth development of Ca2+
alternans in time, and conduction. Experimental characterization
of these dynamics can inform refining of existing models to
analyze mechanisms.
ACCOUNTING FOR PATIENTS’ CONDITION
AND INTER-SUBJECT VARIABILITY
Clinical risk assessment and trial suggest that patient conditions,
i.e., sex (Yang et al., 2017; Vorobyov and Clancy, 2018), age,
disease, electrolyte imbalance (Lazzerini et al.), interaction with
other drugs (Lv et al.) should all be taken into account in risk
assessment (Lane and Tinker)—which is not yet addressed by
CiPA efforts. Along the same lines, Wisniowska et al. reviewed
the different sources of variability (both intrinsic and extrinsic)
that exist in the human population in response to drug action,
and emphasized the need of accounting for these aspects in
modeling approaches for safety pharmacology. Two studies
by the Rodriguez group establish the potential of population-
based approaches as very powerful in silico tools for safety
pharmacology investigations. Passini et al. showed that human in
silico drug trials using repolarization abnormality quantification
as the main metric do better than animal models in detecting
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drugs with TdP risk. They also show agreement of in silico
predictions and two established experimental models (rabbit
wedge ECGs and hiPSC-CMs). Other statistical methods, e.g.,
logistic regression, have been previously employed to assess the
proarrhythmic risk in a population of computational model
variants (Lee et al., 2013; Morotti and Grandi, 2017). Calibrated
populations of models of heart cells could generally reproduce
experimental drug effects on human tissue for dofetilide, whereas
lack of agreement between experiments and simulations for
quinidine and verapamil suggest further work is needed to
understand the more complex electrophysiological effects of
these multichannel blocking drugs (Britton et al.).
USE OF IPSC-CMS FOR SAFETY
PHARMACOLOGY
Because iPSC-CMs are a readily-obtainable and renewable source
of human cardiac myocytes, they are gaining popularity as a
platform to screen drugs for toxicity testing. However, given the
iPSC immature phenotype, and phenotypic differences across
iPSC-CM cell lines (Lei et al.), it remains unclear how well
drug tests performed in iPSC-CMs will recapitulate the effects
observed in adult human cardiomyocytes and hearts. Koivumaki
et al. developed a computational model of the iPSC-CMs
that recapitulates the cells’ immature phenotype, and explore
differences in ionic behavior underlying the AP in paced vs.
spontaneous modes, phenotypic variability in iPSC-CMs, and
iPSC-CM model’s ability to recapitulate physiological properties
of adult cells. Recently, statistical methods have also been
established to provide accurate predictions of adult myocyte drug
responses from iPSC-CM simulations (Gong and Sobie, 2018).
iPSC-CM utilization in drug discovery and safety investigations
is reviewed by Ortega et al. An important advancement in
the technological approach of improving the utility of iPSC-
CMs for safety pharmacology is the augmentation of IK1 using
dynamic clamp. Plagued by low-throughput, Goversen et al. have
moved toward demonstrating that such dynamic clamp can be
performed in a high throughput manner. Bjork et al. reported
that the expression of optogenetic tools in iPSC-CMs did not
significantly affect the baseline electrophysiological properties
of these cells, thus allowing electrophysiological assessments
comparable to conventional patch clamp studies. Nevertheless,
adult human ventricular cardiomyocytes (Nguyen et al.) and
trabeculae (Qu et al.) might still be a more reliable model to
test the cardiotoxic risk associated with novel drugs, with some
advantages over animal and iPSC models.
CONCLUSIONS AND FUTURE
DIRECTIONS
There is a growing body of work supporting the integration
of new and established computational and experimental
approaches to understanding and predicting the risk of
TdP. While mechanistic systems modeling is mature in
the cardiac arrhythmia field, use of similar approaches can
improve understanding and prediction of cardiotoxicity caused
by other drugs, e.g., cancer therapeutics (Shim et al.).
Given the focus on TdP and QT interval, however, the
deleterious effects of drugs on cardiac function are evaluated
only in terms of changes in electrophysiological properties.
Future work should therefore extend the current paradigm to
include other major cellular functions (such as contraction,
energetics, and cell death, i.e., via apoptosis), which dysregulation
can severely impact cardiac performance. In addition to
cardiotoxicity, safety pharmacology aims to determine the
potential undesirable pharmacodynamic effects of a drug on
the central nervous, vascular and respiratory systems (Pugsley
et al., 2008). Thus, extension of the described approaches
to these systems seems desirable, and might contribute
to further advancement of these key areas of biomedical
research.
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